系统性红斑狼疮患者 COVID-19 疫苗接种后与眼部不良事件的时间关联：病例报告。
An ocular adverse event in temporal association with COVID-19 vaccination in a patient with systemic lupus erythematosus: a case report.
机构信息
College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
出版信息
Hum Vaccin Immunother. 2021 Nov 2;17(11):4102-4104. doi: 10.1080/21645515.2021.1976036. Epub 2021 Oct 7.
Abstract
After the COVID-19 pandemic, vaccines using inactivated viruses have attracted worldwide attention for the prevention of infectious diseases. Here, we report a patient who suffered from Systemic Lupus Erythematosus (SLE) for six years and developed ocular symptoms within 72 hours after being vaccinated for COVID-19. The patient presented bilateral conjunctival congestion, eyelid edema with pruritus, and suffered from severe headaches. Recovery occurred within 10 days after the onset of symptoms after treatment with anti-infection drugs. The early identification and extensive assessment of side effects help ensuring effective vaccine safety monitoring.
摘要
在 COVID-19 大流行之后，用于预防传染病的灭活病毒疫苗引起了全球关注。在这里，我们报告了一位患有系统性红斑狼疮 (SLE) 六年的患者，在接种 COVID-19 疫苗后 72 小时内出现眼部症状。患者表现为双眼结膜充血、眼睑水肿伴瘙痒，并伴有严重头痛。在开始出现症状后 10 天内，经抗感染药物治疗后症状缓解。早期识别和广泛评估副作用有助于确保有效的疫苗安全性监测。
相似文献
1
An ocular adverse event in temporal association with COVID-19 vaccination in a patient with systemic lupus erythematosus: a case report.
Hum Vaccin Immunother. 2021 Nov 2;17(11):4102-4104. doi: 10.1080/21645515.2021.1976036. Epub 2021 Oct 7.
2
Attitudes towards and safety of the SARS-CoV-2 inactivated vaccines in 188 patients with systemic lupus erythematosus: a post-vaccination cross-sectional survey.
Clin Exp Med. 2023 Jun;23(2):457-463. doi: 10.1007/s10238-022-00832-1. Epub 2022 May 25.
3
Clinical features of newly diagnosed systemic lupus erythematosus after SARS-CoV-2 vaccination.
Mod Rheumatol Case Rep. 2023 Dec 29;8(1):63-68. doi: 10.1093/mrcr/rxad036.
4
Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus.
Clin Rheumatol. 2022 May;41(5):1349-1357. doi: 10.1007/s10067-021-05980-5. Epub 2021 Nov 16.
5
Systemic Lupus Erythematosus and COVID-19.
Curr Rheumatol Rep. 2023 Oct;25(10):192-203. doi: 10.1007/s11926-023-01110-z. Epub 2023 Jul 21.
6
Systemic lupus erythematosus and antiphospholipid syndrome after COVID-19 vaccination. A case report.
Mod Rheumatol Case Rep. 2023 Jan 3;7(1):43-46. doi: 10.1093/mrcr/rxac018.
7
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
Lupus Sci Med. 2022 Aug;9(1). doi: 10.1136/lupus-2022-000727.
8
Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management.
Clin Rheumatol. 2022 Sep;41(9):2893-2910. doi: 10.1007/s10067-022-06227-7. Epub 2022 May 31.
9
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.
RMD Open. 2021 Dec;7(3). doi: 10.1136/rmdopen-2021-002019.
10
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
引用本文的文献
1
Tubulointerstitial nephritis and uveitis syndrome (TINU) following COVID-19 vaccination.
Am J Ophthalmol Case Rep. 2023 Sep;31:101869. doi: 10.1016/j.ajoc.2023.101869. Epub 2023 Jun 10.
2
The Implications of SARS-CoV-2 Infection in a Series of Neuro-Ophthalmological Manifestations-Case Series and Literature Review.
J Clin Med. 2023 May 31;12(11):3795. doi: 10.3390/jcm12113795.
3
Ocular adverse effects of COVID-19 vaccines: A systematic review.
J Family Med Prim Care. 2022 Sep;11(9):5041-5054. doi: 10.4103/jfmpc.jfmpc_747_22. Epub 2022 Oct 14.
4
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.
J Autoimmun. 2022 Oct;132:102898. doi: 10.1016/j.jaut.2022.102898. Epub 2022 Aug 24.
本文引用的文献
1
Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China.
Expert Rev Vaccines. 2021 Jul;20(7):891-898. doi: 10.1080/14760584.2021.1925112. Epub 2021 May 13.
2
Ocular adverse events following vaccination: overview and update.
Surv Ophthalmol. 2022 Mar-Apr;67(2):293-306. doi: 10.1016/j.survophthal.2021.04.001. Epub 2021 Apr 16.
3
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Oct 15;21(1):853. doi: 10.1186/s13063-020-04775-4.
4
Exploration of vascular adhesion protein-1 expression in patients with conjunctivitis associated systemic lupus erythematosus using 2D-DIGE.
Exp Ther Med. 2019 Dec;18(6):5072-5077. doi: 10.3892/etm.2019.8009. Epub 2019 Sep 16.
5
Update: Vaccines in primary immunodeficiency.
J Allergy Clin Immunol. 2018 Feb;141(2):474-481. doi: 10.1016/j.jaci.2017.12.980. Epub 2017 Dec 27.
6
Acute Bilateral Photoreceptor Degeneration in an Infant After Vaccination Against Measles and Rubella.
JAMA Ophthalmol. 2017 May 1;135(5):478-482. doi: 10.1001/jamaophthalmol.2017.0380.
7
Ocular manifestations in systemic lupus erythematosus.
Br J Ophthalmol. 2016 Jan;100(1):135-41. doi: 10.1136/bjophthalmol-2015-306629. Epub 2015 Apr 22.
8
Systemic lupus erythematosus disease activity index 2000.
J Rheumatol. 2002 Feb;29(2):288-91.
Zotero 插件